Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MindBio Therapeutics Corp. is a biotechnology company focused on the development of psychedelic-based medicines, with a specific emphasis on microdosing applications. The company operates within the biopharmaceutical and mental health therapeutics industries, aiming to develop regulated, prescription-based treatments derived from psychedelic compounds. Its core strategic focus is on addressing mental health conditions such as depression, anxiety, and other neuropsychiatric disorders through clinically validated microdosing protocols.
The company’s primary value proposition lies in its emphasis on take-home microdosing, which differentiates it from many psychedelic medicine developers pursuing high-dose, clinic-administered therapies. MindBio Therapeutics Corp. was founded in 2019 and has since evolved from an early-stage research entity into a clinical-stage company conducting regulated human trials. The company is publicly traded in the United States on the OTC Markets under the ticker MBQIF and is headquartered in New York, United States, with core operations in New Zealand.
Business Operations
MindBio Therapeutics Corp.’s operations are centered on the research and development of psychedelic microdosing treatments, primarily using lysergic acid diethylamide (LSD). The company generates no material commercial revenue and remains in the clinical development stage, with expenditures focused on clinical trials, regulatory compliance, and intellectual property development. Its lead programs are designed to evaluate safety, tolerability, and efficacy of repeated low-dose psychedelic administration.
Operationally, the company conducts clinical trials through regulated frameworks in New Zealand, where psychedelic research is permitted under government-approved protocols. MindBio controls its clinical data, trial methodologies, and formulation approaches, while leveraging external research organizations for trial execution. Data inconclusive based on available public sources regarding material long-term commercial partnerships or revenue-generating subsidiaries.
Strategic Position & Investments
MindBio Therapeutics Corp.’s strategy is focused on establishing scientific and regulatory leadership in the microdosing segment of the psychedelic therapeutics market. Growth initiatives center on advancing clinical trials, expanding intellectual property related to dosing regimens, and generating peer-reviewed clinical data to support future regulatory submissions. The company positions microdosing as a potentially scalable and patient-accessible alternative to supervised psychedelic therapy models.
The company has not disclosed any material acquisitions or controlling interests in other operating companies. Strategic investments are primarily internal, directed toward clinical research, regulatory engagement, and data generation. Emerging areas of interest include digital monitoring tools and longitudinal mental health outcome measurement, although publicly available disclosures do not confirm active technology investments beyond clinical trial infrastructure.
Geographic Footprint
MindBio Therapeutics Corp. maintains its corporate headquarters in New York, United States, while its primary clinical and research operations are based in New Zealand, a jurisdiction known for permitting regulated psychedelic research. This geographic structure allows the company to access international capital markets while conducting trials in a favorable regulatory environment.
The company does not currently report commercial operations across multiple continents, and its footprint remains concentrated in North America and Oceania. International influence is primarily limited to regulatory engagement and scientific collaboration rather than broad operational deployment. Data inconclusive based on available public sources regarding expansion into additional jurisdictions.
Leadership & Governance
MindBio Therapeutics Corp. is led by executives with backgrounds in biotechnology, mental health advocacy, and emerging therapeutics. Leadership has emphasized a vision centered on evidence-based psychedelic medicine, regulatory compliance, and patient-accessible treatment models. The company operates under a standard public-company governance structure consistent with OTC-listed issuers.
Key executives include:
- Justin Hanka – Chief Executive Officer
- Paul McIntyre – Chief Scientific Officer
- Ian McDonald – Executive Chairman
- William H. Rosen – Chief Financial Officer
Leadership communications consistently highlight a strategy focused on disciplined clinical validation, regulatory alignment, and differentiation through microdosing research rather than recreational or wellness positioning.